Forodesine

CHEMBL218291 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
266.2 g/mol
LogP
-2.3
Phase
4

An investigational purine nucleoside phosphorylase inhibitor that disrupts the metabolism of deoxyguanosine in lymphoid cells, leading to selective death of malignant T-cells. It has been studied for the treatment of T-cell leukemia and lymphoma. This targeted mechanism offers a potentially more selective approach compared to conventional chemotherapy.

الوزن الجزيئي

266,2500 g/mol

LogP

-2,30

TPSA

130,00 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

آلية العمل

Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12

InChI

InChI=1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1

Molecular Formula

C11H14N4O4

HBD / HBA

6 / 6

الروابط القابلة للدوران

2

الذرات الثقيلة

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

An investigational purine nucleoside phosphorylase inhibitor that disrupts the metabolism of deoxyguanosine in lymphoid cells, leading to selective death of malignant T-cells. It has been studied for the treatment of T-cell leukemia and lymphoma. This targeted mechanism offers a potentially more selective approach compared to conventional chemotherapy.

Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

Yes, Forodesine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL218291. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 135409409. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.